Free AI-powered Mobile App for Skin Diseases Coming Soon
April 27, 2021 10:30 ET
|
Skinopathy
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Skinopathy Inc., a Canadian medical technology company, will soon release a revolutionary skin disease mobile app that will change how we practice...
GetSkinHelp.com launches service that reduces wait times to see a dermatologist from several months to mere hours
March 11, 2021 10:30 ET
|
Skinopathy
TORONTO, March 11, 2021 (GLOBE NEWSWIRE) -- Skinopathy Inc., a Canadian medical technology company, is expanding and introducing a new service through its flagship platform, GetSkinHelp.com, that...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
July 02, 2020 11:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis
March 24, 2020 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy...
Skin health startup Derm-Biome Pharmaceuticals, Inc. to receive funding from the Government of Canada
July 09, 2019 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 09, 2019 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health, is excited to...
Devonian annonce l’initiation de l’étude clinique de Phase IIa du Thykamine(MC) chez les patients atteints de Dermatite Atopique légère à modérée
November 09, 2017 08:45 ET
|
Groupe Santé Devonian Inc.
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 09 nov. 2017 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. (« Devonian » ou la « Société ») (TSX...
Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine™ in Adult patients with Mild-to-Moderate Atopic Dermatitis
November 09, 2017 08:45 ET
|
Devonian Health Group Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES QUEBEC CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ("Devonian" or the "Corporation")...
Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference
May 02, 2017 08:05 ET
|
Abeona Therapeutics Inc
--EB-101 Demonstrates Significant Wound Healing (defined as greater than 50% healed) in 100% of Treated Wounds (36/36) at 3 Months; 89% (32/36) at 6 months, 83% (20/24) at 12 months, 88% (21/24) at 24...